Sulodexide: A renewed interest in this glycosaminoglycan

Cardiovascular Drug Reviews

Volumn 24, Issue 3-4, 2006, Pages 214-226

  Lauver, D Adam ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulants; Diabetic nephropathy; Glycosaminoglycans; Reperfusion injury; Sulodexide; Vessel

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; GLYCOSAMINOGLYCAN; HEPARIN; PLACEBO; SULODEXIDE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; FIBRINOLYTIC AGENT;

ALBUMINURIA; ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; COMPLEMENT SYSTEM; DEEP VEIN THROMBOSIS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FIBRINOLYSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HUMAN; HYPERLIPIDEMIA; INTERMITTENT CLAUDICATION; LEG ULCER; LIPOLYSIS; LOW DRUG DOSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN SECRETION; REPERFUSION INJURY; REVIEW; THROMBIN TIME; THROMBOGENESIS; THROMBUS; VASCULAR DISEASE; ANIMAL;

ALBUMINURIA; ANIMALS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; DIABETIC NEPHROPATHIES; FIBRINOLYTIC AGENTS; GLYCOSAMINOGLYCANS; HUMANS; MYOCARDIAL REPERFUSION INJURY;

EID: 33847767217     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00214.x     Document Type: Review

References (78)

1. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005;18:568-574.
2. Andriuoli G, Mastacchi R, Barbanti M. Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats. Thromb Res 1984;34:81-86.
3. Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci USA 2002;99:11079-11084.
4. Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res 1992;22:179-184.
5. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein- associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther 2002;303:1007-1013.
6. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995;29:629-636.
7. Buchanan MR, Brister SJ, Ofosu F. Prevention and treatment of thrombosis: novel strategies arising from our understanding the healthy endothelium. Wien Klin Wochenschr 1993;105:309-313.
8. Buchanan MR, Liao P, Smith LJ, Ofosu FA. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of heparin cofactor II. Thromb Res 1994; 74:463-475.
9. Callas DD, Hoppensteadt DA, Jeske W, et al. Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide. Semin Thromb Hemost 1993;19(Suppl 1):49-57.
10. Casu B. Structural features and binding properties of chondroitin sulfates, dermatan sulfate, and heparan sulfate. Semin Thromb Hemost 1991;17(Suppl 1):9-14.
11. Ceol M, Nerlich A, Baggio B, et al. Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996;74:484-495.
12. Ceriello A, Quatraro A, Marchi E, Barbanti M, Giugliano D. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: Effects of the glycosaminoglycan sulodexide. Diabete Metab 1993;19:225-229.
13. Cerletti C, Rajtar G, Marchi E, de Gaetano G. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost 1994;20:245-253.
14. Cirujeda JL, Granado PC. Astudy on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology 2006;57:53-64.
15. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002;87:947-952.
16. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J 2002;23:1057-1065.
17. Corral J, Aznar J, Gonzalez-Conejero R, et al. Homozygous deficiency of heparin cofactor II: Relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation 2004;110:1303-1307.
18. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res 2003;109:333-339.
19. Crepaldi G, Fellin R, Calabro A, et al. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. Monogr Atheroscler 1986;14:215-221.
20. Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabro A. Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res 1992;18:189-195.
21. Cristofori M, Mastacchi R, Barbanti M, Sarret M. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats. Arzneimittelforschung 1985;35:1513-1516.
22. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006;32(Suppl 1):3-15.
23. de Beer FC, Baltz ML, Munn EA, et al. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 1982;45:55-70.
24. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32:219-226.
25. Diabetes Control and Complications Trial. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
26. Ehrlich J, Stivala SS. Chemistry and pharmacology of heparin. J Pharm Sci 1973;62:517-544.
27. Errichi BM, Cesarone MR, Belcaro G, et al. Prevention of recurrent deep venous thrombosis with sulodexide: The SanVal registry. Angiology 2004;55:243-249.
28. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab 2000;26(Suppl 4:64-66.
29. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994;75:701-710.
30. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806.
31. Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992;42:285-291.
32. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615-1625.
33. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994;46:797-806.
34. Gralinski MR, Driscoll EM, Friedrichs GS, DeNardis MR, Lucchesi BR. Reduction of myocardial necrosis after glycosaminoglycan administration: Effects of a single intravenous administration of heparin or N-acetylheparin 2 hours before regional ischemia and reperfusion. J Cardiovasc Pharmacol Ther 1996;1:219-228.
35. Gralinski MR, Wiater BC, Assenmacher AN, Lucchesi BR. Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the rabbit isolated heart from human complement-mediated damage. Immunopharmacology 1996;34:79-88.
36. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999;190:1733-1740.
37. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 1998;18:1-20.
38. Harper PL, Daly M, Price J, Edgar PF, Carrell RW. Screening for heparin binding variants of antithrombin. J Clin Pathol 1991;44:477-479.
39. Hong TT, White AJ, Lucchesi BR. Dermatan disulfate (Intimatan) prevents complement-mediated myocardial injury in the human-plasma-perfused rabbit heart. Int Immunopharmacol 2005;5:381-391.
40. Hornstra G, Vendelmans-Starrenburg A. Induction of experimental arterial occlusive thrombi in rats. Atherosclerosis 1973;17:369-382.
41. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-380.
42. Huntington JA, Carrell RW. The serpins: Nature's molecular mousetraps. Sci Prog 2001;84:125-136.
43. Jorpes JE. Heparin, its chemistry, pharmacology and clinical use. Am J Med 1962;33:692-702.
44. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135-2147.
45. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 1994;28:437-444.
46. Kilgore KS, Naylor KB, Tanhehco EJ, et al. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 1998;285:987-994.
47. Kilgore KS, Tanhehco EJ, Naylor KB, Lucchesi BR. Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. J Pharmacol Exp Ther 1999;290:1041-1047.
48. Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther 2005;312:794-800.
49. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
50. Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. J Biol Chem 2001;276:20959-20965.
51. Libersan D, Khalil A, Dagenais P, et al. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc Res 1998;37:656-666.
52. Linhardt RJ, al-Hakim A, Liu JA, et al. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol 1991;42:1609-1619.
53. Mauro M, Palmieri GC, Palazzini E, Barbanti M, Calanni Rindina F, Milani MR. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation. Curr Med Res Opin 1993;13:87-95.
54. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-689.
55. Nijmeijer R, Lagrand WK, Lubbers YT, et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003;163:269-275.
56. Noti C, Seeberger PH. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans. Chem Biol 2005;12:731-756.
57. Nugent MA. Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci USA 2000;97:10301-10303.
58. Olson ST, Bjork I. Role of protein conformational changes, surface approximation and protein cofactors in heparin-accelerated antithrombin- proteinase reactions. Adv Exp Med Biol 1992;313:155-165.
59. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992;267:12528-12538.
60. Park JL, Kilgore KS, Naylor KB, Booth EA, Murphy KL, Lucchesi BR. N-Acetylheparin pretreatment reduces infarct size in the rabbit. Pharmacology 1999;58:120-131.
61. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-1912.
62. Radhakrishnamurthy B, Sharma C, Bhandaru RR, Berenson GS, Stanzani L, Mastacchi R. Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis 1986;60:141-149.
63. Rajtar G, Marchi E, de Gaetano G, Cerletti C. Effects of glycosaminoglycans on platelet and leucocyte function: Role of N-sulfation. Biochem Pharmacol 1993;46:958-960.
64. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011.
65. Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Invest Med 1998;46:391-395.
66. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-1133.
67. Ruggeri A, Guizzardi S, Franchi M, Morocutti M, Mastacchi R. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung 1985;35:1517-1519.
68. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 1986;137:1945-1949.
69. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-33296.
70. Tanhehco EJ, Kilgore KS, Naylor KB, Park JL, Booth EA, Lucchesi BR. Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J Cardiovasc Pharmacol 1999;34:153-161.
71. Thomas DP, Merton RE, Barrowcliffe TW. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs. Ann NY Acad Sci 1989;556:313-322.
72. Thourani VH, Brar SS, Kennedy TP, et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000;278:H2084-2093.
73. Volanakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982;389:235-250.
74. Volanakis JE. Complement-induced solubilization of C-reactive protein-pneumococcal C-polysaccharide precipitates: Evidence for covalent binding of complement proteins to C-reactive protein and to pneumococcal C-polysaccharide. J Immunol 1982;128:2745-2750.
75. Volanakis JE, and Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: Requirement for human C1q. J Immunol 1974;113:9-17.
76. Westhuyzen J, and Healy H. Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000;30:133-143.
77. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, and Hack CE. CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996;157:473-479.
78. Yeh ET, Anderson HV, Pasceri V, and Willerson JT. C-reactive protein: Linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.